vs
Palomar Holdings, Inc.（PLMR）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Palomar Holdings, Inc.的季度营收约是Ultragenyx Pharmaceutical Inc.的1.2倍（$253.4M vs $207.3M），Palomar Holdings, Inc.同比增速更快（62.7% vs 25.9%），Palomar Holdings, Inc.自由现金流更多（$409.0M vs $-100.8M），过去两年Palomar Holdings, Inc.的营收复合增速更高（46.2% vs 38.0%）
Palomar Holdings, Inc.是一家专业保险控股企业，主要为存在巨灾风险敞口的住宅及商业资产提供财产保险产品，业务范围覆盖美国全境，核心业务板块包含地震、洪水、风暴等高危财产保障服务。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
PLMR vs RARE — 直观对比
营收规模更大
PLMR
是对方的1.2倍
$207.3M
营收增速更快
PLMR
高出36.8%
25.9%
自由现金流更多
PLMR
多$509.8M
$-100.8M
两年增速更快
PLMR
近两年复合增速
38.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $253.4M | $207.3M |
| 净利润 | — | $-128.6M |
| 毛利率 | — | — |
| 营业利润率 | 28.7% | -54.7% |
| 净利率 | — | -62.0% |
| 营收同比 | 62.7% | 25.9% |
| 净利润同比 | — | 3.5% |
| 每股收益（稀释后） | $2.05 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PLMRRARE
| Q4 25 | $253.4M | $207.3M | ||
| Q3 25 | $244.7M | $159.9M | ||
| Q2 25 | $203.3M | $166.5M | ||
| Q1 25 | $174.6M | $139.3M | ||
| Q4 24 | $155.8M | $164.6M | ||
| Q3 24 | $148.5M | $139.5M | ||
| Q2 24 | $131.1M | $147.0M | ||
| Q1 24 | $118.5M | $108.8M |
净利润PLMRRARE
| Q4 25 | — | $-128.6M | ||
| Q3 25 | $51.5M | $-180.4M | ||
| Q2 25 | $46.5M | $-115.0M | ||
| Q1 25 | $42.9M | $-151.1M | ||
| Q4 24 | — | $-133.2M | ||
| Q3 24 | $30.5M | $-133.5M | ||
| Q2 24 | $25.7M | $-131.6M | ||
| Q1 24 | $26.4M | $-170.7M |
营业利润率PLMRRARE
| Q4 25 | 28.7% | -54.7% | ||
| Q3 25 | 27.4% | -106.9% | ||
| Q2 25 | 29.5% | -64.8% | ||
| Q1 25 | 30.8% | -102.6% | ||
| Q4 24 | 28.9% | -74.3% | ||
| Q3 24 | 25.9% | -94.6% | ||
| Q2 24 | 25.5% | -79.1% | ||
| Q1 24 | 29.0% | -151.9% |
净利率PLMRRARE
| Q4 25 | — | -62.0% | ||
| Q3 25 | 21.0% | -112.8% | ||
| Q2 25 | 22.9% | -69.0% | ||
| Q1 25 | 24.6% | -108.5% | ||
| Q4 24 | — | -80.9% | ||
| Q3 24 | 20.5% | -95.7% | ||
| Q2 24 | 19.6% | -89.5% | ||
| Q1 24 | 22.3% | -156.8% |
每股收益（稀释后）PLMRRARE
| Q4 25 | $2.05 | $-1.28 | ||
| Q3 25 | $1.87 | $-1.81 | ||
| Q2 25 | $1.68 | $-1.17 | ||
| Q1 25 | $1.57 | $-1.57 | ||
| Q4 24 | $1.29 | $-1.34 | ||
| Q3 24 | $1.15 | $-1.40 | ||
| Q2 24 | $1.00 | $-1.52 | ||
| Q1 24 | $1.04 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $106.9M | $421.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $942.7M | $-80.0M |
| 总资产 | $3.1B | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资PLMRRARE
| Q4 25 | $106.9M | $421.0M | ||
| Q3 25 | $111.7M | $202.5M | ||
| Q2 25 | $81.3M | $176.3M | ||
| Q1 25 | $119.3M | $127.1M | ||
| Q4 24 | $80.4M | $174.0M | ||
| Q3 24 | $86.5M | $150.6M | ||
| Q2 24 | $47.8M | $480.7M | ||
| Q1 24 | $61.4M | $112.3M |
股东权益PLMRRARE
| Q4 25 | $942.7M | $-80.0M | ||
| Q3 25 | $878.1M | $9.2M | ||
| Q2 25 | $847.2M | $151.3M | ||
| Q1 25 | $790.4M | $144.2M | ||
| Q4 24 | $729.0M | $255.0M | ||
| Q3 24 | $703.3M | $346.8M | ||
| Q2 24 | $532.6M | $432.4M | ||
| Q1 24 | $501.7M | $140.3M |
总资产PLMRRARE
| Q4 25 | $3.1B | $1.5B | ||
| Q3 25 | $2.9B | $1.2B | ||
| Q2 25 | $2.8B | $1.3B | ||
| Q1 25 | $2.4B | $1.3B | ||
| Q4 24 | $2.3B | $1.5B | ||
| Q3 24 | $2.3B | $1.5B | ||
| Q2 24 | $2.0B | $1.6B | ||
| Q1 24 | $1.9B | $1.3B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $409.1M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $409.0M | $-100.8M |
| 自由现金流率自由现金流/营收 | 161.4% | -48.6% |
| 资本支出强度资本支出/营收 | 0.1% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $700.6M | $-472.0M |
8季度趋势，按日历期对齐
经营现金流PLMRRARE
| Q4 25 | $409.1M | $-99.8M | ||
| Q3 25 | $83.6M | $-91.4M | ||
| Q2 25 | $120.9M | $-108.3M | ||
| Q1 25 | $87.2M | $-166.5M | ||
| Q4 24 | $261.2M | $-79.3M | ||
| Q3 24 | $100.3M | $-67.0M | ||
| Q2 24 | $55.1M | $-77.0M | ||
| Q1 24 | $33.1M | $-190.7M |
自由现金流PLMRRARE
| Q4 25 | $409.0M | $-100.8M | ||
| Q3 25 | $83.6M | $-92.7M | ||
| Q2 25 | $120.8M | $-110.7M | ||
| Q1 25 | $87.1M | $-167.8M | ||
| Q4 24 | $260.9M | $-79.5M | ||
| Q3 24 | $100.1M | $-68.6M | ||
| Q2 24 | — | $-79.0M | ||
| Q1 24 | — | $-193.9M |
自由现金流率PLMRRARE
| Q4 25 | 161.4% | -48.6% | ||
| Q3 25 | 34.2% | -58.0% | ||
| Q2 25 | 59.4% | -66.5% | ||
| Q1 25 | 49.9% | -120.5% | ||
| Q4 24 | 167.5% | -48.3% | ||
| Q3 24 | 67.4% | -49.2% | ||
| Q2 24 | — | -53.7% | ||
| Q1 24 | — | -178.2% |
资本支出强度PLMRRARE
| Q4 25 | 0.1% | 0.5% | ||
| Q3 25 | 0.0% | 0.8% | ||
| Q2 25 | 0.0% | 1.5% | ||
| Q1 25 | 0.0% | 1.0% | ||
| Q4 24 | 0.2% | 0.1% | ||
| Q3 24 | 0.1% | 1.2% | ||
| Q2 24 | 0.0% | 1.4% | ||
| Q1 24 | 0.0% | 3.0% |
现金转化率PLMRRARE
| Q4 25 | — | — | ||
| Q3 25 | 1.63× | — | ||
| Q2 25 | 2.60× | — | ||
| Q1 25 | 2.03× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 3.29× | — | ||
| Q2 24 | 2.14× | — | ||
| Q1 24 | 1.26× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PLMR
暂无分部数据
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
